Combination Chemotherapy Plus Thalidomide in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Completed · Phase 2
Conditions studied: Lung Cancer
In brief
RATIONALE: Thalidomide may stop the growth of cancer by stopping blood flow to the tumor. Combining thalidomide with chemotherapy may kill more tumor cells and be an effective treatment for stage IIIB or stage IV non-small cell lung cancer. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy plus thalidomide in treating patients who have stage IIIB or stage IV non-small cell lung cancer.
Key facts
- Study ID
- NCT00025285
- Run by
- Wake Forest University Health Sciences
- People needed
- 46
- Starts
- 2001-11-01
- Expected to finish
- 2004-09-29
- Last updated by the study team
- 2021-09-09
Who can join
Age: 18 and older, up to 120. Sex: any. Healthy volunteers: not accepted.
Where it is running
- CCOP - Central Illinois — Decatur, Illinois, United States
- Southeastern Medical Oncology Center — Goldsboro, North Carolina, United States
- Comprehensive Cancer Center at Wake Forest University — Winston-Salem, North Carolina, United States
- CCOP - Greenville — Greenville, South Carolina, United States
- CCOP - Upstate Carolina — Spartanburg, South Carolina, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.